Sean Maduck's departure as President of Corcept Therapeutics Inc was reported, effective October 1, 2026; the filing names no successor. As of November 6, 2026, Corcept Therapeutics Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 23, 2026, naming 1 departure (Form 8-K, September 23, 2026).
Who owns Corcept Therapeutics Inc.?
CORCEPT THERAPEUTICS INC announced the departure of its President on Sep 23. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Corcept Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Corcept Therapeutics Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-23. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Corcept Therapeutics Inc files it.
Also on the record for Corcept Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 8.9% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Renaissance Technologies LLC | 4.9% of the class | 5%+ stakes | Source |
| April 21, 2026 | Stake report, Schedule 13G/A, by INGALLS & SNYDER LLC | 6.8% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Renaissance Technologies LLC | 5.47% of the class | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 10.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Corcept Therapeutics Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Corcept Therapeutics Inc and the records around it.
Corcept Therapeutics Inc elsewhere on the record
Companies that share a holder
- Renaissance Technologies LLC also filed stake reports on 46 other companies: AMERICAN PUBLIC EDUCATION INC (Aug 2026), Bolt Biotherapeutics, Inc. (Aug 2026), Commercial Vehicle Group, Inc. (Aug 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Corcept Therapeutics Inc
Get an email when Corcept Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Corcept Therapeutics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Corcept Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Corcept Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-23 | Out | President | 2026-10-01 | 8-K, 2026-09-23 |
Who leads Corcept Therapeutics Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President: Sean Maduck, departure reported, effective 2026-10-01 (filed 2026-09-23). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Corcept Therapeutics Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the President at Corcept Therapeutics Inc, with the record behind each one.
Find candidates like President at Corcept Therapeutics IncEvery change, in the filing's words
Departing: Sean Maduck, President, effective 2026-10-01
On September 22, 2026, Sean Maduck, the President of Corcept Endocrinology, notified the Board of Directors of Corcept Therapeutics Incorporated (the "Company") of his decision to resign effective as of October 1, 2026.
- The Company thanks Mr. Maduck for his significant contributions to the Company and his dedication to helping patients.
- Mr. Maduck did not resign because of any disagreement with the Company on any matter relating to the Company's operations, financial statements, policies or practices.
- In connection with Mr. Maduck's resignation, the Company and Mr. Maduck entered into a Consulting Services Agreement (the "Agreement"), dated as of September 22, 2026 and effective as of October 1, 2026, pursuant to which Mr. Maduck will provide consulting services to the Company's Chief Executive Officer and executive management team.
- The Agreement has an initial term expiring on September 30, 2027, unless earlier terminated.
- Pursuant to the Agreement, Mr. Maduck will be paid a cash fee of $57,000 per month.
- The Agreement further provides that during Mr. Maduck's consulting term with the Company, Mr. Maduck's previously awarded and currently outstanding stock options shall continue to vest according to the original vesting schedule of each such stock option.
- Either party may terminate the Agreement upon thirty (30) days' prior written notice.
Tools for this story
Each opens in a new tab, filled in for Corcept Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.